Clicky

GT Biopharma, Inc.(GTBP)

Description: GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase 1 clinical trial; GTB-C3550, a next-generation follow-on to its lead candidates TriKE, GTB-3550, and GTB-C3550, which contains a modified CD16 moiety; and GTB-1615, a single-chain fusion protein for the treatment of solid tumors. Its central nervous system portfolio consists of GTP-004 for the treatment of myasthenia gravis, PainBrake to treat chronic neuropathic pain, and GTP-011 for the treatment of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is headquartered in Westlake Village, California.


Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Solid Tumors Cancer Therapies Myasthenia Gravis Lectins Immuno Oncology Products Motion Sickness Cd22 Chronic Neuropathic Pain Coronavirus Infection Treatment Of Myasthenia Gravis

Home Page: www.gtbiopharma.com

GTBP Technical Analysis

8000 Marina Boulevard
Brisbane, CA 94005
United States
Phone: 415 919 4040


Officers

Name Title
Mr. Michael Martin Breen Interim CEO & Exec. Chairman
Dr. Gregory I. Berk M.D. Pres of R&D, Chief Medical Officer and Member of Scientific Advisor Board
Dr. Gavin S. Choy MBA, PharmD Chief Clinical Devel. Officer
Mr. Manu Ohri Chief Financial Officer
Dr. Jeffrey S. Miller M.D. Consulting Chief Scientific Officer & Scientific Advisor
Ms. Stacy Herb M.B.A., M.P.H. Sr. VP of Portfolio Management

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.8572
Price-to-Sales TTM: 0
IPO Date: 2017-09-22
Fiscal Year End: December
Full Time Employees: 8
Back to stocks